Trials / Sponsors / Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Industry · 7 registered clinical trials.

Status	Trial	Phase	Started
Terminated	A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable Synovial Sarcoma, Cancer, Soft Tissue Sarcoma	Phase 3	2018-09-18
Terminated	Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodg Follicular Low Grade Non-Hodgkin's Lymphoma	Phase 1 / Phase 2	2016-02-03
Terminated	Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants Wit Sarcoma, Myxoid/Round Cell Liposarcoma, Synovial Sarcoma	Phase 2	2015-04-29
Terminated	Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing N Sarcoma, Melanoma, Non-small Cell Lung Cancer	Phase 1	2015-02-28
Completed	Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed, Sarcoma - Enrollment Completed	Phase 1	2014-05-30
Completed	A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Merkel Cell Carcinoma	Phase 1	2014-01-01
Completed	A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer Melanoma, Ovarian Cancer, Sarcoma	Phase 1	2013-11-01